The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC ...

The U.S. Securities and Exchange Commission has reportedly asked issuers behind proposed Solana (SOL-USD) exchange-traded ...

Clene is continuing to work with U.S. regulators on its plans to seek accelerated approval of CNM-Au8 for the treatment of ...

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

The FDA approves a rapid test for identifying patients with NSCLC eligible for sunvozertinib, enhancing timely, precision ...

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...